New Treatment Options in Elderly Patients with Diffuse Large B-cell Lymphoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jul 19

PMID 37465115

Authors

Annalisa Arcari

Federica Cavallo

Benedetta Puccini

Daniele Vallisa

Affiliations

Soon will be listed here.

Abstract

Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (>65 years of age) and this population is expected to increase in the following years. A simplified geriatric assessment based on a careful evaluation of the fitness status and comorbidities is essential to choose the correct intensity of treatment. Fit older patients can benefit from a standard immunochemotherapy, while unfit/frail patients frequently need reduced doses or substitution of particular agents with less toxic ones. This review focuses on new therapies (e.g., polatuzumab vedotin, tafasitamab, bispecific antibodies) that have indicated promising results in relapsed/refractory patients, particularly in cases not eligible to transplant. Some of these new drugs have been tested as single agents or in combinations as first-line treatment, aiming to improve the outcome of the traditional chemotherapy. If preliminary efficacy and safety data are confirmed in future clinical trials, a chemo-free immunotherapic approach could become an alternative option to offer a curative treatment even in frail patients.

Citing Articles

Prognostic impact of concordant and discordant bone marrow involvement on diffuse large B-cell lymphoma.

Zuo H, Xie X, Sun X, Shi H, Pei X, Sun M Transl Cancer Res. 2024; 13(10):5339-5346.

PMID: 39525001 PMC: 11543059. DOI: 10.21037/tcr-24-238.

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Ekels A, van de Poll-Franse L, Issa D, Hoogendoorn M, Nijziel M, Koster A Ann Hematol. 2024; 103(12):5511-5525.

PMID: 39279019 DOI: 10.1007/s00277-024-06006-1.

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature.

Yamasaki S Hematol Rep. 2024; 16(2):317-330.

PMID: 38921180 PMC: 11204029. DOI: 10.3390/hematolrep16020032.

Feasibility of Quality of Life Assessment in Patients with Lymphoma Aged ≥80 Years Receiving Reduced-Intensity Chemotherapy: A Single-Institute Study.

Yamasaki S Hematol Rep. 2024; 16(1):1-10.

PMID: 38247991 PMC: 10801517. DOI: 10.3390/hematolrep16010001.

Letter regarding "Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma".

Hsiao C, Liaw Y Clin Mol Hepatol. 2023; 30(1):109-110.

PMID: 37817733 PMC: 10776285. DOI: 10.3350/cmh.2023.0373.

References

Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F . The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011; 96(12):1888-90. PMC: 3232277. DOI: 10.3324/haematol.2011.050617. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer M . Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2009; 21(7):1492-1499. DOI: 10.1093/annonc/mdp544. View

Munshi P, Chen Y, Ahn K, Awan F, Cashen A, Shouse G . Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2022; 28(8):487.e1-487.e7. PMC: 9375438. DOI: 10.1016/j.jtct.2022.05.029. View

Storti S, Spina M, Pesce E, Salvi F, Merli M, Ruffini A . Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the . Haematologica. 2018; 103(8):1345-1350. PMC: 6068040. DOI: 10.3324/haematol.2017.186569. View

Sancho J, Fernandez-Alvarez R, Gual-Capllonch F, Gonzalez-Garcia E, Grande C, Gutierrez N . R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 2021; 10(4):1314-1326. PMC: 7926012. DOI: 10.1002/cam4.3730. View

Pettengell R, Coiffier B, Narayanan G, Hurtado de Mendoza F, Digumarti R, Gomez H . Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012; 13(7):696-706. DOI: 10.1016/S1470-2045(12)70212-7. View

Peyrade F, Bologna S, Delwail V, Emile J, Pascal L, Ferme C . Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017; 4(1):e46-e55. DOI: 10.1016/S2352-3026(16)30171-5. View

Tilly H, Gomes Da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A . Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v116-25. DOI: 10.1093/annonc/mdv304. View

10.

Younes A, Sehn L, Johnson P, Zinzani P, Hong X, Zhu J . Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019; 37(15):1285-1295. PMC: 6553835. DOI: 10.1200/JCO.18.02403. View

11.

Wiernik P, Lossos I, Tuscano J, Justice G, Vose J, Cole C . Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26(30):4952-7. DOI: 10.1200/JCO.2007.15.3429. View

12.

Merli F, Luminari S, Tucci A, Arcari A, Rigacci L, Hawkes E . Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021; 39(11):1214-1222. DOI: 10.1200/JCO.20.02465. View

13.

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

14.

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L . Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019; 33(4):1047-1051. PMC: 6756077. DOI: 10.1038/s41375-018-0320-9. View

15.

Jacobson C, Locke F, Ma L, Asubonteng J, Hu Z, Siddiqi T . Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022; 28(9):581.e1-581.e8. PMC: 9427701. DOI: 10.1016/j.jtct.2022.05.026. View

16.

Westin J, Davis R, Feng L, Hagemeister F, Steiner R, Lee H . Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2022; 41(4):745-755. PMC: 10489211. DOI: 10.1200/JCO.22.00597. View

17.

Nastoupil L, Jain M, Feng L, Spiegel J, Ghobadi A, Lin Y . Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128. PMC: 7499611. DOI: 10.1200/JCO.19.02104. View

18.

Visco C, Pregnolato F, Ferrarini I, De Marco B, Bonuomo V, Sbisa E . Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Crit Rev Oncol Hematol. 2021; 163:103377. DOI: 10.1016/j.critrevonc.2021.103377. View

19.

Goy A . Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials. J Clin Oncol. 2017; 35(31):3519-3522. DOI: 10.1200/JCO.2017.74.7360. View

20.

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A, Rube C . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3):634-41. DOI: 10.1182/blood-2003-06-2095. View